Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

TSX:BCT - Post Discussion

View:
Post by Iseneschal on Jun 29, 2020 2:35pm

Screw u

Mr. MM .....I will watch this continue to "slow bleed"

The trend is not the shareholders friend
Comment by Iseneschal on Jul 30, 2020 6:19am
One month later......... sold all shares for 75% profit.... Thx Mr. MM. My mother loves you. Cheers!
Comment by Pandora on Jul 30, 2020 7:19pm
Slightly different numbers for me.  One month later ...... sold all shares (100 that were left) for a 60% gain at the time --- this 60% gain resulted in only having a 75% total loss from my original purchase price. Nobody to thank and only myself to kick. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities